TABLE 3.
Issuance of PGX drugs over 7-year period (2011–2017) in Netherlands.
| PGX Drugs | Issuance (Thousand) | % | Therapeutic area |
| 6-Mercaptopurine | 136 | 0.04 | oncology |
| Abacavir | 116 | 0.03 | infectious |
| Acenocoumarol | 9,149 | 2.38 | Cardiovascular |
| Allopurinol | 6,210 | 1.62 | other |
| Aripiprazole | 1,625 | 0.42 | psychiatry/neurology |
| Azathioprine | 1,093 | 0.28 | oncology |
| Capecitabine | 297 | 0.08 | oncology |
| Carbamazepine | 3,033 | 0.79 | psychiatry/neurology |
| Clopidogrel | 10,195 | 2.65 | Cardiovascular |
| Contraceptives with Estrogen | 7,842 | 2.04 | endocrinology |
| Efavirenz | 145 | 0.04 | infectious |
| Flecainide | 1,806 | 0.47 | Cardiovascular |
| Flucloxacillin | 2,459 | 0.64 | infectious |
| Fluorouracil | 312 | 0.08 | oncology |
| Haloperidol | 2,678 | 0.70 | psychiatry/neurology |
| Metoprolol | 61,224 | 15.93 | Cardiovascular |
| Proton Pump Inhibitors (PPI) | 110,147 | 28.66 | gastroenterology |
| Opioids | 28,559 | 7.43 | analgesic/anaesthesiology |
| Phenprocoumon | 1,821 | 0.47 | Cardiovascular |
| Phenytoin | 1,028 | 0.27 | psychiatry/neurology |
| Pimozide | 599 | 0.16 | psychiatry/neurology |
| Propafenone | 97 | 0.03 | Cardiovascular |
| SSRI | 27,424 | 7.14 | Psychiatry/neurology |
| Simvastatin and Atorvastatin | 80,653 | 20.98 | Cardiovascular |
| Tacrolimus | 977 | 0.25 | other |
| Tamoxifen | 1,193 | 0.31 | oncology |
| Tegafur | 0.812 | 0.00 | oncology |
| Thioguanine | 53 | 0.01 | oncology |
| Tricyclic antidepressants | 15,034 | 3.91 | psychiatry/neurology |
| Venlafaxine | 7,698 | 2.00 | Psychiatry/neurology |
| Voriconazole | 24 | 0.01 | Infectious |
| Zuclopenthixol | 722 | 0.19 | psychiatry/neurology |
| Total PGX drugs issued | 384,351 | ||
| Total prescribed drugs (PGX and non-PGX drugs) | 1,600,241 | ||
| % of PGX drugs among all medications | 24.02% |